<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">Tuberculous</z:e> <z:hpo ids='HP_0001287'>meningitis</z:hpo> (TBM) is a fairly common, debilitating disease and is often complicated by <z:hpo ids='HP_0012089'>arteritis</z:hpo> resulting in <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Few treatment regimes specifically address this condition </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011105'>Hypervolemia</z:hpo>-<z:hpo ids='HP_0000822'>hypertension</z:hpo>-hemodilution (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e>) regime is known to be effective for treatment of vasospasm complicating <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the efficacy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> regime in patients with TBM with <z:hpo ids='HP_0012089'>arteritis</z:hpo> using a prospective, randomized study design </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND METHODS: Patients diagnosed to have TB <z:hpo ids='HP_0001287'>meningitis</z:hpo> by clinical, CSF, and imaging findings were evaluated for <z:hpo ids='HP_0012089'>arteritis</z:hpo>, which was recognized by presence of focal neurologic deficits with or without corresponding focal hypodensities on brain CT scan </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with deficits of &lt; 96 h were randomized to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> or conservative treatment </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patents received four-first-line anti-TB drugs and Inj.<z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> therapy was administered over 3-9 days </plain></SENT>
<SENT sid="8" pm="."><plain>Neurologic status and modified Rankin score were noted serially and at discharge </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Seven patients received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> and 5, conservative treatment </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had <z:hpo ids='HP_0001269'>hemiparesis</z:hpo> with power 0-3/5 </plain></SENT>
<SENT sid="11" pm="."><plain>Median GCS was worse in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> group (11 vs. 13) </plain></SENT>
<SENT sid="12" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> group, 6/7 improved in motor power, and 5/7 in sensorium </plain></SENT>
<SENT sid="13" pm="."><plain>In the control group, 3/5 improved in motor power and 3/5 in sensorium </plain></SENT>
<SENT sid="14" pm="."><plain>Four patients died in each group </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HHH</z:e> therapy is safe and may be beneficial in the management of patients with infective <z:hpo ids='HP_0012089'>arteritis</z:hpo> secondary to TBM </plain></SENT>
<SENT sid="16" pm="."><plain>Further study in a larger group with improved monitoring of cerebral circulation is indicated </plain></SENT>
</text></document>